Answers are grounded in this paper and cite their sources.
The US Preventative Services Task Force has no guidelines on the screening for nonalcoholic fatty liver disease (NAFLD), and the American Association for the Study of Liver Diseases (AASLD) guidance does not recommend population screening for NAFLD.1 A reference cited by this guidance concluded that screening is not cost-effective2; however, new data have emerged since then. We hypothesize that screening for NAFLD in patients with type 2 diabetes (T2D), starting with ultrasound (US) and alanine aminotransferase or aspartate aminotransferase and followed by noninvasive testing for fibrosis to detect those most likely to have fibrosis stage ≥F2, is more cost-effective than not screening this population.
No takes yet. Share an insight, caveat, or question.
Noureddin et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: